STAT
OCTOBER 29, 2024
The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare Drug Price Negotiation Program.
STAT
DECEMBER 12, 2024
During 2023, drugmakers substantially raised prices on five widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $815 million last year, according to a new report.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 13, 2025
For the moment, the state has not fined the company, although it may yet do so, according to a consent order. A department spokesperson declined to comment. However, the audit was released two months after Express Scripts had been ordered to pay a $250,000 fine for failing to reimburse a pharmacy.
Drug Patent Watch
DECEMBER 26, 2024
The FDA has also demonstrated that greater competition among generic drug makers can lead to lower generic drug prices. Studies have shown that the market entry of just a few generic competitors can yield generic prices below the brand price, and that generic drug prices decline with additional competition.
Drug Channels
JUNE 16, 2025
drug pricing, reimbursement, and dispensing system. For 2024, DCI estimates that total prescription dispensing revenues at retail, mail, long-term care, and specialty pharmacies reached $683 billion, up 9% from the 2023 figure. It’s the 16th edition of our popular and comprehensive examination of the entire U.S.
Putting Patients First Blog
JUNE 26, 2025
The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy. This will allow other stakeholders (e.g.,
pharmaphorum
JUNE 12, 2025
Importantly, this type of insight also supports smarter negotiations around drug pricing. In communities where there is only one pharmacy – or none – there is no competition to drive down prices. By identifying these regions, PBMs can better advocate for fair pricing models that reflect real-world access challenges.
Expert insights. Personalized for you.
301 
Let's personalize your content